What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy.
ApexOnco Front Page
Recent articles
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
